Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (5) , 533-542
- https://doi.org/10.2165/00019053-199916050-00009
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Meeting HighlightsCirculation, 1998
- Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome PatientsCirculation, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997
- Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery DiseaseCirculation, 1997
- Use of Cardiac Procedures and Outcomes in Elderly Patients with Myocardial Infarction in the United States and CanadaNew England Journal of Medicine, 1997
- Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemiaJournal of the American College of Cardiology, 1995
- Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.Circulation, 1994
- Biochemical evidence of platelet activation in patients with persistent unstable anginaJournal of the American College of Cardiology, 1987
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981